Clinical and Pharmacogenetic Characterization to Predict Cost-Effectiveness of Rituximab (Rtx) Therapy in Rheumatoid Arthritis (RA)

Trial Profile

Clinical and Pharmacogenetic Characterization to Predict Cost-Effectiveness of Rituximab (Rtx) Therapy in Rheumatoid Arthritis (RA)

Not stated
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2011

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 15 Jun 2011 New trial record
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top